184 related articles for article (PubMed ID: 25181429)
1. Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps.
Roberts PL
Biotechnol Prog; 2014; 30(6):1341-7. PubMed ID: 25181429
[TBL] [Abstract][Full Text] [Related]
2. Virus elimination during the recycling of chromatographic columns used during the manufacture of coagulation factors.
Roberts PL
Biologicals; 2014 Jul; 42(4):184-90. PubMed ID: 24981392
[TBL] [Abstract][Full Text] [Related]
3. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
5. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
6. Pathogen safety of intravenous Rh immunoglobulin liquid and other immune globulin products: enhanced nanofiltration and manufacturing process overview.
Soluk L; Price H; Sinclair C; Atalla-Mikhail D; Genereux M
Am J Ther; 2008; 15(5):435-43. PubMed ID: 18806519
[TBL] [Abstract][Full Text] [Related]
7. Pathogen safety of human C1 esterase inhibitor concentrate.
Gröner A; Nowak T; Schäfer W
Transfusion; 2012 Oct; 52(10):2104-12. PubMed ID: 22413956
[TBL] [Abstract][Full Text] [Related]
8. Inactivation and clearance of viruses during the manufacture of high purity factor IX.
Johnston A; Macgregor A; Borovec S; Hattarki M; Stuckly K; Anderson D; Goss NH; Oates A; Uren E
Biologicals; 2000 Sep; 28(3):129-36. PubMed ID: 10964439
[TBL] [Abstract][Full Text] [Related]
9. Purification of antibodies by precipitating impurities using Polyethylene Glycol to enable a two chromatography step process.
Giese G; Myrold A; Gorrell J; Persson J
J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Nov; 938():14-21. PubMed ID: 24036248
[TBL] [Abstract][Full Text] [Related]
10. Analysis of viral clearance unit operations for monoclonal antibodies.
Miesegaes G; Lute S; Brorson K
Biotechnol Bioeng; 2010 Jun; 106(2):238-46. PubMed ID: 20073086
[TBL] [Abstract][Full Text] [Related]
11. Removal of viruses from human intravenous immune globulin by 35 nm nanofiltration.
Troccoli NM; McIver J; Losikoff A; Poiley J
Biologicals; 1998 Dec; 26(4):321-9. PubMed ID: 10403036
[TBL] [Abstract][Full Text] [Related]
12. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
13. Pathogen safety of a pasteurized four-factor human prothrombin complex concentrate preparation using serial 20N virus filtration.
Nowak T; Popp B; Gröner A; Schäfer W; Kalina U; Enssle K; Roth NJ
Transfusion; 2017 May; 57(5):1184-1191. PubMed ID: 28191640
[TBL] [Abstract][Full Text] [Related]
14. A tandem laboratory scale protein purification process using Protein A affinity and anion exchange chromatography operated in a weak partitioning mode.
Shamashkin M; Godavarti R; Iskra T; Coffman J
Biotechnol Bioeng; 2013 Oct; 110(10):2655-63. PubMed ID: 23633385
[TBL] [Abstract][Full Text] [Related]
15. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
16. [Validation of the virus inactivation capacity of a procedure of human plasma albumin purification by chromatography].
Stoltz JF; Geschier C; Rivat C; Sertillanges P; Grandgeorges M; Liautaud J; Regnault V; Dumont L
Ann Pharm Fr; 1993; 51(2):78-93. PubMed ID: 8250488
[TBL] [Abstract][Full Text] [Related]
17. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
18. Virus filtration of high-concentration monoclonal antibody solutions.
Marques BF; Roush DJ; Göklen KE
Biotechnol Prog; 2009; 25(2):483-91. PubMed ID: 19353736
[TBL] [Abstract][Full Text] [Related]
19. Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.
Radomski KU; Lattner G; Schmidt T; Römisch J
BioDrugs; 2017 Apr; 31(2):125-134. PubMed ID: 28236170
[TBL] [Abstract][Full Text] [Related]
20. Prediction of viral filtration performance of monoclonal antibodies based on biophysical properties of feed.
Rayfield WJ; Roush DJ; Chmielowski RA; Tugcu N; Barakat S; Cheung JK
Biotechnol Prog; 2015; 31(3):765-74. PubMed ID: 25919945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
